Stone, Julie A.
Merck & Co., Inc., Rahway, NJ, USA (United States)
3 papers on CoChatORCID 0000-0002-4914-4828
Most cited papers
- Verified
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
Egan, M. F., Mukai, Y., Voss, T., Kost, J., Stone, J., Furtek, C., Mahoney, E., Cummings, J. L., Tariot, P. N., Aisen, P. S., et al. (2019) · Alzheimer's Research & Therapy
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 81
- Verified
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis
Stone, J. A., McCrea, J. B., Witter, R., Zajic, S., & Stoch, S. A. (2019) · British Journal of Clinical Pharmacology
Bone health and osteoporosis researchBone Metabolism and Diseases
Cited by 66
- Verified
Immunogenicity of pembrolizumab in patients with advanced tumors
van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., et al. (2019) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersBiosimilars and Bioanalytical Methods
Cited by 57
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free